Haleon
Haleon plc is a British consumer healthcare enterprise specializing in the development, manufacturing, and marketing of over-the-counter medicines, oral health products, and wellness supplements. The company operates across five core product categories, comprising Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements. Primary revenue drivers stem from global retail sales of established consumer health brands, including Sensodyne, Panadol, Voltaren, Advil, Theraflu, and Centrum. Key end markets include retail pharmacies, supermarket chains, online e-commerce platforms, and mass merchants, serving individual consumers across international regions. The firm focuses on consumer-led innovation, regulatory execution, and clinical research to expand its self-care product portfolio for daily personal health. Haleon holds a world-leading market position as a pure-play consumer health company by global retail revenue. The company is headquartered in Weybridge, United Kingdom, and its ordinary shares trade on the London Stock Exchange and New York Stock Exchange under tickeren HLN.
91 of the funds FundTelligence covers report a position in Haleon.
- Legal name
- HALEON PLC
- Sector
- Consumer Staples
- Country
- United Kingdom
- Funds holding it
- 91
Funds holding Haleon
- Schroder ISF Global Consumer Trends — Schroders · 4.26 % (full portfolio disclosed, December 2025)
- Franklin Mutual U.S. Value Fund — Franklin Templeton · 2.43 % (full portfolio disclosed, September 2026)
- Schroder ISF Global Sustainable Growth — Schroders · 2.11 % (full portfolio disclosed, June 2026)
- Nordea European Sustainable Stars — Nordea Funds · 2.05 % (full portfolio disclosed, September 2026)
- Nordea Europa — Nordea Funds · 2.05 % (full portfolio disclosed, September 2026)
- BlackRock iShares MSCI Europe Health Care Sector UCITS ETF — BlackRock · 2.02 % (full portfolio disclosed, October 2026)
- Schroder ISF Global Climate Leaders — Schroders · 1.77 % (full portfolio disclosed, June 2026)
- Nordea Robeco Biodiversity Equities — Nordea Funds · 1.71 % (full portfolio disclosed, August 2026)
Showing the 8 largest of 91 funds holding it.